February 11, 2020 04:59 AM EST
R&D
Pharma

With block­buster dreams, Ex­elix­is is look­ing for some re­demp­tion for cabo in prostate can­cer. It won’t be easy

John Carroll

Editor & Founder

Back a lit­tle over 5 years ago, I re­port­ed on a ma­jor dis­as­ter for Ex­elix­is $EX­EL when cabozan­ti­nib flopped in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Up­dat­ed: Bio­gen makes cuts across its re­search unit, shift­ing fo­cus to ‘ex­ter­nal op­por­tu­ni­ties’

'No mir­a­cles': What Re­gen­eron's George Yan­copou­los re­al­ly thinks of AI

GLP-1s can cut the risk of Alzheimer’s. What does that mean for No­vo Nordisk?

RFK Jr. says he’ll di­vest in­ter­ests in CRISPR Ther­a­peu­tics if con­firmed for HHS chief

Chi­nese start­up be­gins first tri­al of in vi­vo CRISPR ther­a­py for blood dis­ease

sponsored

Fu­el­ing More Break­throughs: Man­u­fac­tur­ing In­no­va­tion to Ex­pand Gene Ther­a­py’s Reach

A service from the Financial Times